Navigation Links
Elbit Imaging Ltd. Announces Second Quarter Results for 2012
Date:8/30/2012

attributable to an increase in the interest expenses related to the activity of Plaza Centers' commercial centers.
  • Other revenues, net in Q2 2012 amounted to NIS 3 million (US$ 0.8 million) compared to expenses in the amount of NIS 23 million in Q2 2011.
  • Loss for Q2 2012 amounted to NIS 132 million (US$ 33.6 million) (out of which NIS 141 is attributed to the equity holders of the Company) compared to gain in the amount of NIS 14 million in the corresponding period in 2011 (out of which a loss in the amount of NIS 30 million is attributed to the equity holders of the Company).
  • Cash and cash equivalents as of June 30, 2012 amounted to NIS 1.5 billion (US$ 380 million) compared to NIS 0.6 billion as of December 31, 2011. The increase is attributable to the sale of 47 out of 49 US investment properties and to the sale of four Dutch hotels, as aforementioned.

    • Shareholders' equity as of June 30, 2012 amounted to NIS 1.7 billion (US$ 430 million) (out of which NIS 0.4 billion is attributed to the equity holders of the Company) compared to NIS 1.5 billion (out of which NIS 0.4 billion is attributed to the equity holders of the Company) as of December 31, 2011. In the current quarter, the Company has initially implemented the revaluation model with respect to the Company's property, plant and equipment (mainly the hotels segment), which contributed to an increase in the Company's equity.

    Our presentation to the consolidated financial statements for the second quarter of 2012 is available through our website at: http://www.elbitimaging.com under: "Investor Relations - Company Presentations (06/2012)."

     

    About Elbit Imaging Ltd.


    Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction an
    '/>"/>

    SOURCE Elbit Imaging Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    2. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
    3. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
    4. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
    5. Real Time Medical to Feature Diagnostic Imaging Software @ Innovation Showcase at e-Health 2012
    6. ClearCanvas Partners With DPR to Offer CaseReader™, an Integrated Technology Structured Reporting Solution for Medical Imaging Professionals
    7. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
    8. Global Market for Medical Imaging Equipment to Reach $25.3 Billion as Retiring Boomers and Emerging Markets Demand Better Healthcare
    9. IMD Adds Substantial Imaging Contracts
    10. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
    11. Derry Medical and Derry Imaging Select Calypso for Website Redesign
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
    (Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
    (Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
    Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
    ... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
    ... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
    Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
    (Date:6/19/2013)... CCA , America's leader in partnership ... Vice President, Health Services, effective June 8, 2013. ... for CCA. He will replace the retiring Herb ... to lead CCA's dedicated team of health care professionals. ... and our partners as we provide effective care to ...
    (Date:6/19/2013)... (PRWEB) June 19, 2013 Strict ... In July 2013, Orriant is launching a new ... and maintain compliance with regulations. New HHS ... receive wellness incentives if their employer offers outcome-based, ... have been compliant with these standards for nearly ...
    (Date:6/19/2013)... Citi Bike has come to New York City ... Perna to know for sure how many patients will choose to ... have the option. In fact, he’s happy about anything that ... make it more convenient for them to visit his office at ... Complimentary Alternative Medicine at Back and Body Medical and an experienced ...
    (Date:6/19/2013)... surgery have had a significant impact on survival ... injuries, including burns. Patients who survive the ... greatest risk from infections particularly the overwhelming, ... from inflammation-induced multiorgan failure. Now, a device ... measures the movement of key immune cells may ...
    (Date:6/19/2013)... (June 19, 2013) The results of three important ... Neurosurgery , official journal of the Congress ... by Lippincott Williams & Wilkins , a part ... indicates that continuous "machine learning" using artificial neural networks ... patients with advanced brain cancers. Another study in the ...
    Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3
    ... leukemia, also shows promise against a type of stomach cancer ... a promising anti-leukemia drug for treatment of a relatively rare ... pill once a day, is effective in treating both forms ... cancer cells without attacking healthy cells and causing severe side ...
    ... mothers can modify the length of other women's menstrual ... mother - or their infants - made the cycles ... Ohio University.// ,She suggests this is due to ... as part of a human's desire to raise children ...
    ... Hopkins University School of Medicine have recently found that the ... that lets us stop smelling something, even though the odour ... issue of the journal Science show that a protein called ... job of these reurons is to detect smells and send ...
    ... immune cells which help protect us from disease does not ... it could be something to do with their shape. ... how immune cells behave in microgravity as part of their ... ,It has been found that astronauts have elevated virus levels ...
    ... The Federal Drug Administration approved OxyContin in late 1995 ... early 1996. Between that time and 2000, prescriptions for ... that they could get a powerful heroin-like high by ... powder.// ,Abuse of OxyContin, the nation's best ...
    ... Kava is derived from a leafy plant native to the ... implicated in approximately 25 cases of liver diseases. The herb ... to treat insomnia, anxiety, stress and muscle spasms. According to ... as// benzodiazepines but is not chemically related. ,Benzodiazepines have ...
    Cached Medicine News:Health News:Immune cells halt round in space 2
    Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
    For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
    For the quantitative determination of total glucose in serum....
    Glucose reagent is used for the quantitative determination of glucose in human serum....
    Medicine Products: